PubRank

Jochen Walz

Author PubWeight™ 60.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2007 2.50
2 Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy. Eur Urol 2006 2.21
3 Cryo-electron tomography provides novel insights into nuclear pore architecture: implications for nucleocytoplasmic transport. J Mol Biol 2003 2.05
4 High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol 2007 2.02
5 Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2005 1.97
6 Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 2008 1.90
7 Development and external validation of an extended 10-core biopsy nomogram. Eur Urol 2006 1.90
8 Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol 2012 1.81
9 Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. Eur Urol 2007 1.51
10 Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J 2009 1.51
11 Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int 2007 1.50
12 Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol 2007 1.45
13 Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Eur Urol 2007 1.45
14 Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol 2006 1.42
15 Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008 1.39
16 The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. Eur Urol 2006 1.38
17 Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007 1.36
18 Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer 2007 1.19
19 External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol 2008 1.18
20 Open retropubic nerve-sparing radical prostatectomy. Eur Urol 2005 1.16
21 Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. BJU Int 2006 1.15
22 Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 2007 1.09
23 A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 2007 1.08
24 Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 2010 1.06
25 Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer 2007 1.05
26 Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol 2006 1.02
27 Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 2011 1.02
28 Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009 1.02
29 External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 2010 1.01
30 A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008 1.01
31 Development and external validation of an extended repeat biopsy nomogram. J Urol 2007 1.00
32 Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World J Urol 2014 0.96
33 Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. Eur J Cancer 2007 0.94
34 Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int 2012 0.94
35 Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int 2014 0.93
36 Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy. Eur J Cancer 2006 0.93
37 Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis? Eur Urol 2005 0.93
38 Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer. BJU Int 2007 0.92
39 A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. BJU Int 2007 0.91
40 Surgery for high-risk localized prostate cancer. Ther Adv Urol 2011 0.86
41 The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Adv Urol 2012 0.85
42 Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy. BJU Int 2007 0.84
43 Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. J Urol 2008 0.84
44 Experiences with a new high-dose-rate brachytherapy (HDR-BT) boost technique for T3b prostate cancer. Strahlenther Onkol 2007 0.84
45 Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sum. J Endourol 2008 0.83
46 Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy. Eur Urol 2006 0.82
47 External validation of a preoperative nomogram for prediction of the risk of recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2009 0.81
48 Short-course radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma: results of a retrospective multi-center study. Eur Urol 2005 0.79
49 The presence of prostate cancer on saturation biopsy can be accurately predicted. BJU Int 2009 0.77
50 External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer. World J Urol 2014 0.77
51 Adjuvant radiotherapy after radical prostatectomy shows no ability to improve rates of overall and cancer-specific survival in a matched case-control study. BJU Int 2008 0.77
52 Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up. World J Surg Oncol 2013 0.77
53 External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy. J Endourol 2007 0.77
54 [Prostate biopsy -- less pain through diclofenac]. Aktuelle Urol 2004 0.75
55 Continuous-wave, double-pass second-harmonic generation with 60% efficiency in a single MgO:PPSLT crystal. Opt Lett 2014 0.75
56 Triple resonant four-wave mixing boosts the yield of continuous coherent vacuum ultraviolet generation. Phys Rev Lett 2012 0.75
57 Prenatally detected cystic adrenal mass associated with Beckwith-Wiedemann syndrome. Fetal Diagn Ther 2004 0.75
58 Do bladder cancer patients with metastatic spinal cord compression benefit from radiotherapy alone? Urology 2007 0.75
59 750 mW continuous-wave solid-state deep ultraviolet laser source at the 253.7 nm transition in mercury. Opt Lett 2007 0.75
60 High accuracy of virtual simulation with the laser system Dorado CT4. Strahlenther Onkol 2007 0.75
61 4W continuous-wave narrow-linewidth tunable solid-state laser source at 546nm by externally frequency doubling a ytterbium-doped single-mode fiber laser system. Opt Express 2007 0.75
62 Continuous-wave spontaneous lasing in mercury pumped by resonant two-photon absorption. Opt Lett 2010 0.75
63 Continuous-wave Lyman-alpha generation with solid-state lasers. Opt Express 2009 0.75